These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 29745925)

  • 1. [Mechanism of action of intravesical BCG. Biological bases and clinical applicability.].
    Carballido JA; Rodríguez Monsalve M
    Arch Esp Urol; 2018 May; 71(4):358-375. PubMed ID: 29745925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Local and systhemic immunotherapy for bladder cáncer: from bench to bedside.].
    Carballido JA; Vázquez Alba D; Rodríguez Monsalve M
    Arch Esp Urol; 2020 Dec; 73(10):879-894. PubMed ID: 33269707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
    Derré L; Cesson V; Lucca I; Cerantola Y; Valerio M; Fritschi U; Vlamopoulos Y; Burruni R; Legris AS; Dartiguenave F; Gharbi D; Martin V; Vaucher L; Speiser DE; Romero P; Jichlinski P; Nardelli-Haefliger D
    Clin Cancer Res; 2017 Feb; 23(3):717-725. PubMed ID: 27521445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is it possible to stop follow-up of patients with primary T1G3 urothelial carcinoma of the bladder managed with intravesical bacille Calmette-Guérin immunotherapy?
    Golabek T; Palou J; Rodríguez O; Gaya JM; Breda A; Villavicencio H
    World J Urol; 2017 Feb; 35(2):237-243. PubMed ID: 27277599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra.
    Giannarini G; Birkhäuser FD; Recker F; Thalmann GN; Studer UE
    Eur Urol; 2014 Apr; 65(4):825-31. PubMed ID: 24144432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients.
    Yossepowitch O; Eggener SE; Bochner BH; Donat SM; Herr HW; Dalbagni G
    J Urol; 2006 Aug; 176(2):482-5. PubMed ID: 16813873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Building on a Solid Foundation: Enhancing Bacillus Calmette-Guérin Therapy.
    Rentsch CA; Derré L; Dugas SG; Wetterauer C; Federer-Gsponer JR; Thalmann GN; Ingersoll MA
    Eur Urol Focus; 2018 Jul; 4(4):485-493. PubMed ID: 30415921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Additive antitumor effect of arsenic trioxide combined with intravesical bacillus Calmette-Guerin immunotherapy against bladder cancer through blockade of the IER3/Nrf2 pathway.
    Mao MH; Huang HB; Zhang XL; Li K; Liu YL; Wang P
    Biomed Pharmacother; 2018 Nov; 107():1093-1103. PubMed ID: 30257321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of previous bacille Calmette-Guérin failure pattern on subsequent response to bacille Calmette-Guérin plus interferon intravesical therapy.
    Gallagher BL; Joudi FN; Maymí JL; O'Donnell MA
    Urology; 2008 Feb; 71(2):297-301. PubMed ID: 18308107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guérin immunotherapy.
    Luo Y; Chen X; Downs TM; DeWolf WC; O'Donnell MA
    J Immunol; 1999 Feb; 162(4):2399-405. PubMed ID: 9973521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravesical instillation therapy with bacillus Calmette-Guérin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Guérin immunotherapy.
    Shintani Y; Sawada Y; Inagaki T; Kohjimoto Y; Uekado Y; Shinka T
    Int J Urol; 2007 Feb; 14(2):140-6. PubMed ID: 17302571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A mathematical model of combined bacillus Calmette-Guerin (BCG) and interleukin (IL)-2 immunotherapy of superficial bladder cancer.
    Bunimovich-Mendrazitsky S; Claude Gluckman J; Chaskalovic J
    J Theor Biol; 2011 May; 277(1):27-40. PubMed ID: 21334346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of intravesical Bacillus Calmette-Guerin instillations on the expression of inducible nitric oxide synthase in humans.
    Mitropoulos D; Petsis D; Kyroudi-Voulgari A; Kouloukoussa M; Zervas A; Dimopoulos C
    Nitric Oxide; 2005 Aug; 13(1):36-41. PubMed ID: 15964223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolution and clinical significance of the T cell proliferative and cytokine response directed against the fibronectin binding antigen 85 complex of bacillus Calmette-Guerin during intravesical treatment of superficial bladder cancer.
    Zlotta AR; Drowart A; Van Vooren JP; de Cock M; Pirson M; Palfliet K; Jurion F; Vanonckelen A; Simon J; Schulman CC; Huygen K
    J Urol; 1997 Feb; 157(2):492-8. PubMed ID: 8996341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of Response to Intravesical Therapy.
    Li R; Kamat AM
    Urol Clin North Am; 2020 Feb; 47(1):23-33. PubMed ID: 31757297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravesical Immunomodulatory Imiquimod Enhances Bacillus Calmette-Guérin Downregulation of Nonmuscle-invasive Bladder Cancer.
    Camargo JA; Passos GR; Ferrari KL; Billis A; Saad MJA; Reis LO
    Clin Genitourin Cancer; 2018 Jun; 16(3):e587-e593. PubMed ID: 29174504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Importance of urinary interleukin-18 in intravesical immunotherapy with bacillus calmette-guérin for superficial bladder tumors.
    Eto M; Koga H; Noma H; Yamaguchi A; Yoshikai Y; Naito S
    Urol Int; 2005; 75(2):114-8. PubMed ID: 16123563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of lubricants on viability of bacillus Calmette-Guerin for intravesical immunotherapy against bladder carcinoma.
    Böhle A; Rüsch-Gerdes S; Ulmer AJ; Braasch H; Jocham D
    J Urol; 1996 Jun; 155(6):1892-6. PubMed ID: 8618281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of neutrophils and TNF-related apoptosis-inducing ligand (TRAIL) in bacillus Calmette-Guérin (BCG) immunotherapy for urothelial carcinoma of the bladder.
    Rosevear HM; Lightfoot AJ; O'Donnell MA; Griffith TS
    Cancer Metastasis Rev; 2009 Dec; 28(3-4):345-53. PubMed ID: 19967427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The current status of intravesical therapy for superficial bladder cancer.
    Patard JJ; Rodriguez A; Lobel B
    Curr Opin Urol; 2003 Sep; 13(5):357-62. PubMed ID: 12917511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.